Common side effects include nausea, vomiting, and mild digestive issues, especially when starting the medication
They are simply nutrient-dense foods marketed toward a specific consumer group
The SURPASS phase 3 clinical trial programme explored the efficacy and safety of tirzepatide in people with type 2 diabetes, and demonstrated dose-dependent reductions in HbA 1c of 2028 mmol/mol in those treated with tirzepatide: greater reductions than those achieved with semaglutide (Fras et al, 2021), insulin degludec (Ludvik et al, 2021) and insulin glargine (Del Prato et al, 2021), with reductions sustained up to 2 years in SURPASS-4
A baseline eye exam and a clear plan for follow-up exams should be part of starting any strong glucose-lowering treatment
Ongoing development of targeted, sustained-release systems and multimodal combination strategies holds promise for improving long-term clinical outcomes and expanding access to individualized treatment
When making coverage decisions, insurers often rely on reviewers with limited or no expertise in the condition, a history of concerning decisions, and no insight into the patients historyyet they make life-changing decisions in minutes